140 related articles for article (PubMed ID: 2097143)
1. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience.
Brumfitt W; Maple PA; Hamilton-Miller JM
Drugs Exp Clin Res; 1990; 16(8):377-83. PubMed ID: 2097143
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
J Antimicrob Chemother; 1989 Apr; 23(4):517-25. PubMed ID: 2526111
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
4. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
O'Hare MD; Felmingham D; Grüneberg RN
Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ramoplanin on staphylococci.
Francis J; Webster H; Newsom SW
Drugs Exp Clin Res; 1990; 16(9):457-60. PubMed ID: 2100247
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Ristow TA; Noskin GA; Warren JR; Peterson LR
Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
J Antimicrob Chemother; 1992 Jun; 29(6):661-8. PubMed ID: 1506349
[TBL] [Abstract][Full Text] [Related]
8. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
[TBL] [Abstract][Full Text] [Related]
10. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents.
Aldridge KE; Gelfand MS; Schiro DD; Barg NL
Diagn Microbiol Infect Dis; 1992; 15(7):601-8. PubMed ID: 1424517
[TBL] [Abstract][Full Text] [Related]
11. Comparative post-antibiotic effect of five antibiotics against ten aerobic gram-positive cocci.
Drabu YJ; Blakemore PH
Drugs Exp Clin Res; 1990; 16(11):557-63. PubMed ID: 2151661
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(3):279-82. PubMed ID: 2507218
[TBL] [Abstract][Full Text] [Related]
13. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
Fitzgibbon MM; Rossney AS; O'Connell B
J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
15. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
[TBL] [Abstract][Full Text] [Related]
16. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method.
Thamlikitkul V
J Med Assoc Thai; 1991 Dec; 74(12):669-74. PubMed ID: 1839906
[TBL] [Abstract][Full Text] [Related]
17. [Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides].
Cantón R; Mir N; Martínez-Ferrer M; Sánchez del Saz B; Soler I; Baquero F
Rev Esp Quimioter; 1999 Mar; 12(1):48-53. PubMed ID: 10896469
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
Lawrence T; Rotstein C; Beam TR; Gorzynski EA; Amsterdam D
Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
Bernard L; Vaudaux P; Rohner P; Huggler E; Armanet M; Pittet D; Lew DP; Schrenzel J
J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
